Investing
CapEx
Alnylam Pharmaceuticals CapEx decreased by 6.3% to $21.83M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 143.4%, from $8.97M to $21.83M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -6.4% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
An increase signals growth investment or infrastructure modernization; a decrease might suggest cost-cutting or a transition to an asset-light model.
Detailed definition
Funds used by a company to acquire, upgrade, and maintain physical assets such as property, plants, buildings, technolog...
Peer comparison
Hardware-focused tech firms typically have higher CapEx relative to revenue than pure software companies due to manufacturing and supply chain needs.
Metric ID:
capital_expendituresHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.25M | $26.06M | $21.89M | $17.86M | $16.06M | $16.51M | $21.64M | $13.89M | $15.92M | $17.09M | $15.31M | $12.97M | $8.02M | $4.19M | $9.09M | $8.97M | $14.29M | $12.14M | $23.29M | $21.83M |
| QoQ Change | — | +131.7% | -16.0% | -18.4% | -10.1% | +2.8% | +31.0% | -35.8% | +14.6% | +7.4% | -10.4% | -15.3% | -38.2% | -47.7% | +116.9% | -1.4% | +59.3% | -15.0% | +91.8% | -6.3% |
| YoY Change | — | — | — | — | +42.8% | -36.7% | -1.1% | -22.2% | -0.8% | +3.5% | -29.2% | -6.6% | -49.6% | -75.5% | -40.6% | -30.9% | +78.3% | +189.6% | +156.1% | +143.4% |
Range$4.19M – $26.06M
CAGR+15.0%
Avg YoY Growth+20.0%
Median YoY Growth-3.9%
CapEx at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's capex?
- Alnylam Pharmaceuticals (ALNY) reported capex of $21.83M in Q1 2026.
- How has Alnylam Pharmaceuticals's capex changed year-over-year?
- Alnylam Pharmaceuticals's capex increased by 143.4% year-over-year, from $8.97M to $21.83M.
- What is the long-term trend for Alnylam Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's capex has grown at a -6.4% compound annual growth rate (CAGR), from $76.37M to $58.70M.
- What does capex mean?
- The money spent on long-term physical assets like machinery, data centers, and office buildings.